Heavier FTC Scrutiny Puts Pressure On Consumer Health Product Claims
This article was originally published in The Tan Sheet
Executive Summary
Attorneys say marketers should make structure/function claims with knowledge that no claims are safe from FTC scrutiny. During the Food & Drug Law Institute annual meeting, stakeholders commented on how FTC’s stance on Bayer Health Care’s Philips Colon Health will impact other claims.
You may also be interested in...
FTC Requests Drug Claim Support For Bayer Probiotic Supplement
On behalf of the FTC, DoJ alleges Bayer violated a 2007 settlement to substantiate supplement claims and asks a court to require the firm to provide two RCTs for dietary supplement claims for Phillips’ Colon Health. Trade groups rally behind the firm, arguing the requirement is unfair and illegal.
Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention
FDA Gets Message In Congress' First Cannabis Policy Hearing: Deliver CBD Regulation
During first-ever congressional hearing on federal policies for lawful use of cannabis, House Energy and Commerce Health Subcommittee Chairwoman Anna Eschoo says with $2m appropriated to develop a regulation on CBD’s use in non-drug products during, FDA should deliver.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: